Cancer care specialist US Oncology has established a full-service contract research organisation (CRO), US Oncology Clinical Development (USOCD).

The new arm formalises many of the services provided since 1999 by US Oncology Research, a physician-led research network specialising in Phase I-IV clinical trials. According to its parent, US Oncology has played a pivotal role in the development of 80% of the cancer drugs most recently approved by the US Food and Drug Administration.

USOCD will offer full-service CRO capabilities with expertise in Phase I clinical trials (inpatient and outpatient, including first-in-human); Phase II-IV clinical trials; physician advisory boards; safety data collection and regulatory submission; data management; biostatistics; medical writing and protocol development; medical monitoring; regulatory document collection and submission; monitoring and auditing; site selection and payments; central institutional review boards; and feasibility data.

“We have built an experienced team that enhances our ability to serve our clients for all of their oncology clinical trial needs,” said Steve Smith, vice president and general manager of research and personalised science. “We will leverage all of the strengths of the US Oncology network and its proven history of accrual performance and commitment to quality.”